NCT04771520: Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KIT, PDGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express either a c-KIT activating mutation OR PDGFRA activating mutation
Exclusions: Patients with c-KIT mutation V654A or T670I; Patients with leptomeningeal disease; Patients with uncontrolled unstable symptomatic brain metastasis- see trial for details

Comments are closed.

Up ↑